Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 8840 Wilshire Blvd, 2nd Floor BEVERLY HILLS CA 90211 |
Tel: | 1-617-4356602 |
Website: | https://capricor.com |
IR: | See website |
Key People | ||
Frank I. Litvack Executive Chairman of the Board | Linda Marban President, Chief Executive Officer, Director | Anthony Bergmann Chief Financial Officer | Karen G. Krasney Executive Vice President, General Counsel |
Business Overview |
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. |
Financial Overview |
For the fiscal year ended 31 December 2023, Capricor Therapeutics Inc revenues increased from $2.6M to $25.2M. Net loss decreased 23% to $22.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Investment income increase from $522K to $1.7M (income), Loss on disposal of fixed assets decrease of 82% to $6K (expense). |
Employees: | 101 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $121.72M as of Dec 31, 2023 |
Annual revenue (TTM): | $25.18M as of Dec 31, 2023 |
EBITDA (TTM): | -$23.01M as of Dec 31, 2023 |
Net annual income (TTM): | -$22.29M as of Dec 31, 2023 |
Free cash flow (TTM): | -$27.64M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 31,502,972 as of Mar 18, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |